Science and Research

HD and sexuality

Sexuality and partnership have an important influence on the quality of life of patients with chronic disorders. There are just a few studies in literature about sexuality in Huntington’s disease which conclude that up to 85% men and up to 75% of women experience high levels of sexual problems, most of them having prevalent symptoms of a hypoactive sexual disorder but also increased sexual interest and paraphilia were found. There is no evidence that sexual dysfunction is mainly a specific
Marsha L. Miller, Ph.D.

Metabolic disorder in Huntington's Disease

The Press Release A metabolic disorder underlies the brain effects found in those with Huntington's disease, researchers report in an advance article which appeared in the November 2006 issue of the journal Cell Metabolism, published by Cell Press. Their new evidence ties a metabolic defect to the loss of neurons in the striatum, the brain's "movement control" region. That neurodegeneration leads to the uncontrollable "dance-like" movements characteristic of the fatal, genetic disorder.
Marsha L. Miller, Ph.D.

Medivation Begins phase 1-2a Trial of Dimebon? in Huntington's Disease

Presented at BIO Investor Forum 2006 on October 19, 2006 9:40a.m. Pacific time SAN FRANCISCO (October 19, 2006) — Medivation, Inc. (AMEX: MDV) today announced that patient dosing has begun for its Phase 1-2a clinical trial of Dimebon™ to treat Huntington's disease. "The initiation of our first clinical trial in Huntington's disease represents an important clinical milestone for Medivation and our second clinical indication for Dimebon™," said David Hung, M.D., president
Steve Ireland

New Website Brings Latest Clinical Research News to Huntington's Disease Families

The Huntington?s disease clinical research team at the Institute of Neurology, University College, London, announces the launch of a new website that will bring the latest news about clinical research in Huntington?s disease (HD) to patients, relatives and carers in the UK and worldwide. The site,, will be a source of the latest information about all clinical research in HD being carried out through the HD Multidisciplinary Clinic of the National Hospital for Neurology an
Steve Ireland

Is Loss of Hearing Caused by HD?

During the national broadcast of the Speech and Swallowing training film several years ago, that the National Center for Neurogenic Communication Disorders produced with the assistance of the HDSA Arizona Affiiliate, one of the professors at the University of Arizona from the Department of Speech and Hearing was intrigued by the comments made by one of the Person's with HD (Phd) being interviewed in the video when she remarked that she had problems understanding what others were saying and didn'
Phil Hardt

2CARE - The Wrong Question

HSG 2CARE At the recent HDSA convention, representatives from the Huntington Study Group (HSG) announced plans for another large CoQ-10 trial (2CARE) testing its effectiveness in Huntington?s disease. We were told that recruiting would likely begin in late winter 2005-2006. 2CARE is to be a large (600 people), long (5 years), and expensive (more than ten million dollars) placebo controlled single drug trial. We were told that the primary funding source will be the National Institute of Neur
LaVonne Veatch Goodman, M.D.

Throughput Assays Identify New Candidates for Treatment

We have developed a medium-throughput cell-based assay to screen drugs for Huntington's Disease (HD). The assay measures the ability of drugs to protect cultured neuronal (PC12) cells from death caused by an expanded polyglutamine (poly Q) form of huntingtin exon 1. Using this assay, we have blindly screened a library of 1040 compounds compiled by the NINDS: the NIH Custom Collection (NCC). Each compound was tested at five concentrations for its ability to protect cells against huntingtin-induce
Aiken CT, Tobin AJ, Schweitzer ES
Syndicate content